Pictures of Jet City
A new study finds that patients taking Eli Lilly (NYSE: LLY)Mounjaro lost more weight than those taking Novo Nordisk (NVO) Ozempic.
The study analyzed the electronic health records of approximately 41,000 obese or overweight patients taking these drugs and found After three months of use, the average Mounjaro user lost 5.9% of their weight, while the average Ozempic user lost 3.6%.
After six months of use, Mounjaro users experienced an average loss of 10.1%, while Ozempic users experienced an average loss of 5.8%. Mounjaro users experienced an average weight loss of 15.3% at 12 months, compared with 8.3% for those using Ozempic. The risk of gastrointestinal adverse events is similar for both drugs.
The study was published Monday in JAMA Internal Medicine.
Mounjaro’s active ingredient is tezepatide, while Ozempic’s active ingredient is semaglutide. Eli Lilly sells zeparatide as Mounjaro for the treatment of diabetes and Zepbound for weight loss.
Likewise, Novo markets semaglutide for diabetes (called Ozempic) and semaglutide for weight loss (called Wegovy).
Tezepatide and semaglutide both belong to a class of drugs called GLP-1.
